Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
Novartis Receives CHMP Opinion For Cosentyx In Adolescents Aged 12+ With Hidradenitis Suppurativa
Novartis eyes Rhapsido’s broader use on positive urticaria data drop
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice
Is Novartis (SWX:NOVN) A Bargain Or Fully Priced Now?
Novartis (SWX:NOVN) Halts Pelacarsen After Trial Miss As Ianalumab Data Impresses
Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
Novartis ranks first place in 2026 Access to Medicine Index
Market Chatter: Novartis to Discontinue Development for Cardiovascular Disease Drug
Novartis shelves potential blockbuster pelacarsen as landmark study fails
Update: Market Chatter: Novartis Reports Two Confirmed Tumor Cases Linked to Neuromuscular Gene Therapy
$1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today
Growth in the Q3 Revenue, Reaching CHF 310.2 Million, an Increase of 10.2% at Constant Exchange Rates
Novartis: 3 Key Takeaways for Long-Term Investors
Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
Deutsche Bank Downgrades Novartis to Sell
Novartis AG (NVS) Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.